211 related articles for article (PubMed ID: 31259762)
1. Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience.
Spano JP; Veyri M; Gobert A; Guihot A; Perré P; Kerjouan M; Brosseau S; Cloarec N; Montaudié H; Helissey C; Flament T; Gounant V; Lavolé A; Poizot-Martin I; Katlama C
AIDS; 2019 Sep; 33(11):F13-F19. PubMed ID: 31259762
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan.
Hsu JC; Lin JY; Hsu MY; Lin PC
PLoS One; 2018; 13(8):e0202725. PubMed ID: 30142174
[TBL] [Abstract][Full Text] [Related]
3. Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.
Inomata M; Kado T; Okazawa S; Imanishi S; Taka C; Kambara K; Hirai T; Tanaka H; Tokui K; Hayashi K; Miwa T; Hayashi R; Matsui S; Tobe K
Anticancer Res; 2019 Dec; 39(12):6887-6893. PubMed ID: 31810958
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer.
Ostios-Garcia L; Faig J; Leonardi GC; Adeni AE; Subegdjo SJ; Lydon CA; Rangachari D; Huberman MS; Sehgal K; Shea M; VanderLaan PA; Cheng MP; Marty FM; Hammond SP; Costa DB; Awad MM
J Thorac Oncol; 2018 Jul; 13(7):1037-1042. PubMed ID: 29631035
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
[TBL] [Abstract][Full Text] [Related]
6. Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France.
Aarnink A; Fumet JD; Favier L; Truntzer C; Ghiringhelli F
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2699-2707. PubMed ID: 32474752
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis.
Almutairi AR; Alkhatib N; Martin J; Babiker HM; Garland LL; McBride A; Abraham I
Crit Rev Oncol Hematol; 2019 Oct; 142():16-25. PubMed ID: 31326706
[TBL] [Abstract][Full Text] [Related]
8. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis.
Ksienski D; Wai ES; Croteau N; Fiorino L; Brooks E; Poonja Z; Fenton D; Geller G; Glick D; Lesperance M
Clin Lung Cancer; 2019 Jan; 20(1):e97-e106. PubMed ID: 30337270
[TBL] [Abstract][Full Text] [Related]
10. A real-world data of Immune checkpoint inhibitors in solid tumors from India.
Noronha V; Abraham G; Patil V; Joshi A; Menon N; Mahajan A; Janu A; Jain S; Talreja VT; Kapoor A; Kumar Singh G; Khaddar S; Gupta K; Rathinasamy N; Srinivas S; Agrawal A; Ventrapati P; Prabhash K
Cancer Med; 2021 Mar; 10(5):1525-1534. PubMed ID: 33591635
[TBL] [Abstract][Full Text] [Related]
11. Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study.
Presotto EM; Rastrelli G; Desideri I; Scotti V; Gunnella S; Pimpinelli N; Vaccher E; Bearz A; Di Costanzo F; Bruggia M; Mini E; Maggi M; Peri A
J Endocrinol Invest; 2020 Mar; 43(3):337-345. PubMed ID: 31542865
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab rechallenge in squamous non-small-cell lung cancer and HIV-positivity: a case report.
Guaitoli G; Barbieri F; Barbolini M; Molinaro E; Emidio KD; Borghi V; Dominici M; Bertolini F
Immunotherapy; 2021 Mar; 13(4):277-281. PubMed ID: 33249929
[TBL] [Abstract][Full Text] [Related]
13. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
[TBL] [Abstract][Full Text] [Related]
14. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population.
Sattar J; Kartolo A; Hopman WM; Lakoff JM; Baetz T
J Geriatr Oncol; 2019 May; 10(3):411-414. PubMed ID: 30104155
[TBL] [Abstract][Full Text] [Related]
16. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases.
Kitadai R; Okuma Y; Hakozaki T; Hosomi Y
J Cancer Res Clin Oncol; 2020 Mar; 146(3):777-785. PubMed ID: 31828427
[TBL] [Abstract][Full Text] [Related]
18. Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade.
Galanina N; Goodman AM; Cohen PR; Frampton GM; Kurzrock R
Cancer Immunol Res; 2018 Oct; 6(10):1129-1135. PubMed ID: 30194084
[TBL] [Abstract][Full Text] [Related]
19. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
20. Medication use evaluation of programmed death-1 inhibitors in a veteran population.
Nguyen V; Huq M
J Oncol Pharm Pract; 2019 Jul; 25(5):1066-1075. PubMed ID: 29726785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
